** Shares of Summit Therapeutics SMMT.O up 13.41% at $31.05 before the bell
** Company and partner Akeso's 9926.HK drug ivonescimab, in combination with chemotherapy, showed "statistically significant superiority" in progression-free survival for patients with a type of lung cancer
** The companies were testing ivonescimab-chemotherapy regime in a study conducted in China, against a tislelizumab, and chemotherapy combination
** Tislelizumab is sold as Tevimbra by BeiGene 688235.SS
** The companies plan to share detailed data from the study later this year and SMMT is currently enrolling patients in a multi-regional study for the drug
** SMMT shares peaked in September 2024 after results from a study in China showed some lung cancer patients on its experimental drug had better survival rates than those on Merck's MRK.N blockbuster Keytruda
** BMO analysts say the data "further heats up competition" in the lung cancer treatment market and can put further pressure on MRK's shares
** As of last close, SMMT shares up 53.26% YTD
(Reporting by Bhanvi Satija in Bengaluru)
((Bhanvi.Satija@thomsonreuters.com; Outside U.S. +91 9873062788;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。